Business Description
Xintela AB
ISIN : SE0007756903
Compare
Compare
Traded in other countries / regions
XINT.Sweden1XT.Germany IPO Date
2016-03-22Description
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.24 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -31.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 29.9 | |||||
| 3-Year EPS without NRI Growth Rate | 33.6 | |||||
| 3-Year FCF Growth Rate | 21.6 | |||||
| 3-Year Book Growth Rate | -66.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.43 | |||||
| 9-Day RSI | 34.55 | |||||
| 14-Day RSI | 39.97 | |||||
| 6-1 Month Momentum % | 16.94 | |||||
| 12-1 Month Momentum % | 6.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.2 | |||||
| Quick Ratio | 1.2 | |||||
| Cash Ratio | 0.56 | |||||
| Days Sales Outstanding | 453.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -65.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -73380.77 | |||||
| Net Margin % | -69343.59 | |||||
| FCF Margin % | -68096.15 | |||||
| ROA % | -286.09 | |||||
| ROIC % | -290.91 | |||||
| ROC (Joel Greenblatt) % | -1933.03 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 30.5 | |||||
| Price-to-Tangible-Book | 24.4 | |||||
| EV-to-EBIT | -2.28 | |||||
| EV-to-EBITDA | -2.45 | |||||
| EV-to-Revenue | 1673.6 | |||||
| EV-to-FCF | -2.53 | |||||
| Earnings Yield (Greenblatt) % | -43.84 | |||||
| FCF Yield % | -38.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xintela AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0.078 | ||
| EPS (TTM) (kr) | -0.153 | ||
| Beta | 0 | ||
| Volatility % | 45.27 | ||
| 14-Day RSI | 39.97 | ||
| 14-Day ATR (kr) | 0.022708 | ||
| 20-Day SMA (kr) | 0.26115 | ||
| 12-1 Month Momentum % | 6.23 | ||
| 52-Week Range (kr) | 0.21 - 0.349 | ||
| Shares Outstanding (Mil) | 567.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xintela AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xintela AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xintela AB Frequently Asked Questions
What is Xintela AB(OSTO:XINT)'s stock price today?
The current price of OSTO:XINT is kr0.24. The 52 week high of OSTO:XINT is kr0.35 and 52 week low is kr0.21.
When is next earnings date of Xintela AB(OSTO:XINT)?
The next earnings date of Xintela AB(OSTO:XINT) is 2024-05-24.
Does Xintela AB(OSTO:XINT) pay dividends? If so, how much?
Xintela AB(OSTO:XINT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers